Officials and members of the public discussed the Medical Psilocybin Treatment Equity Fund, including eligibility and reimbursement
Digital Assignment Editor
Health officials on Friday reviewed a proposed equity fund to help low-income individuals access medical psilocybin treatment.
The board heard public testimony on the proposal as speakers highlighted the potential impact of both the psilocybin program and the fund, including rules addressing eligibility, filing claims, reimbursement, and travel expenses to clinics that provide treatment.
The proposed Medical Psilocybin Treatment Equity Fund could cover the entire treatment for eligible patients. Concerns about treatment access had been raised in previous meetings.
“As a person who plans on working in this new program, I’m really excited that the possibility for people to get access to this treatment without having to pay anything out of pocket is just such a thrill,” said licensed counselor and clinical supervisor Anne Metz of Taos County. “But of course, the equity fund is the biggest piece of what’s going to make that possible.”
No decision was made during the hearing. A report and recommendations will be submitted to the New Mexico health secretary by Dec. 4.
Medical psilocybin, a psychoactive component in “magic mushrooms,” has been used to treat anxiety, depression and PTSD, among other medical issues, in novel programs in Oregon and Colorado.
New Mexico legalized medical psilocybin through the Medical Psilocybin Act, signed into law in April 2025, and the program is set to be fully implemented by the end of 2027.